^
Association details:
| Biomarker: | MSI-L/dMMR |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Investigate the efficacy of immunotherapy for treatment of pancreatic adenocarcinoma (PDAC) with mismatch repair deficiency (dMMR).
Published date:
01/11/2021
Excerpt:
We identified 10 pts with dMMR PDAC….7 pts were treated with ICIs. 3 pts had locally advanced and 4 had metastatic disease when they started ICIs. 5 received Pembrolizumab (pem), 1 received ipilimumab/ nivolumab (ipi/nivo), and 1 received pem then ipi/nivo after progressive disease (PD) on pem....Among 6 evaluable pts, 3 had an objective response (1: complete response and 2: partial response), and 2 had stable disease (SD). Median progression-free survival was 8.2 mo...This series suggest ICIs can provide durable clinical efficacy in pts with dMMR PDAC.
DOI:
10.1200/JCO.2021.39.3_suppl.415
